Drs. Mary Nakamura and Timothy Quinn are developing recombinant fusion proteins that activate death receptors to kill cancer cells. If successful, their work will lead to therapies that specifically target and kill tumors without harming healthy tissue. Since their research findings were very preliminary, they struggled to find funding to support their work. The Catalyst Awards Program recognized the potential value of their early research findings and provided seed funding and expert advice from Drs. Gary Patou and James Swartz to help them identify and address the most critical development risks and better position the project to garner follow-on support. Sign up to receive updates on videos that highlight their work and other passionate researchers at UC San Francisco.
- Date June 21, 2013
- Tags Organizational Support